Ness Ziona, Israel, February 13, 2007 – Kamada (TASE: KMDA), a bio-pharmaceutical developer and manufacturer of prescription drugs, announced today that it has submitted plans to the European Agency for the Evaluation of Medicinal Products (EMEA) for phase II-III clinical trial of its aerosolized formulation of Alpha-1 Antitrypsin [AAT, also known as API - Alpha-1 Proteinase Inhibitor]. The drug was developed by Kamada to treat inborn deficiency of Alpha-1 proteinase inhibitor, which may lead to emphysema.
